See more : Intesa Sanpaolo S.p.A. (IITSF) Income Statement Analysis – Financial Results
Complete financial analysis of H. Lundbeck A/S (HLUN-A.CO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of H. Lundbeck A/S, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Kuala Lumpur Kepong Berhad (KLKBY) Income Statement Analysis – Financial Results
- Torq Resources Inc. (TRBMF) Income Statement Analysis – Financial Results
- HarbourVest Global Private Equity Ltd. (HVPD.L) Income Statement Analysis – Financial Results
- QKL Stores Inc. (QKLS) Income Statement Analysis – Financial Results
- Pono Capital Two, Inc. (PTWOW) Income Statement Analysis – Financial Results
H. Lundbeck A/S (HLUN-A.CO)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.lundbeck.com
About H. Lundbeck A/S
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with FeetMe focusing on the use of sensor shoe soles. H. Lundbeck A/S also has a collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 19.91B | 18.25B | 16.30B | 17.67B | 17.36B | 17.88B | 17.23B | 15.63B | 14.59B | 13.47B | 15.26B | 14.80B | 16.01B | 14.77B | 13.75B | 11.28B | 10.98B | 9.22B | 9.07B | 9.73B |
| Cost of Revenue | 4.49B | 3.95B | 3.65B | 4.17B | 3.39B | 3.46B | 3.88B | 4.08B | 5.40B | 4.16B | 4.04B | 3.33B | 3.17B | 2.96B | 2.66B | 1.84B | 2.20B | 1.65B | 1.49B | 932.90M |
| Gross Profit | 15.43B | 14.30B | 12.65B | 13.50B | 13.97B | 14.42B | 13.35B | 11.55B | 9.20B | 9.31B | 11.22B | 11.48B | 12.84B | 11.81B | 11.09B | 9.44B | 8.79B | 7.58B | 7.58B | 8.80B |
| Gross Profit Ratio | 77.48% | 78.35% | 77.62% | 76.42% | 80.50% | 80.67% | 77.48% | 73.89% | 63.03% | 69.11% | 73.54% | 77.54% | 80.22% | 79.97% | 80.69% | 83.72% | 79.99% | 82.15% | 83.60% | 90.41% |
| Research & Development | 3.46B | 3.75B | 3.82B | 4.55B | 3.12B | 3.28B | 2.71B | 2.97B | 8.15B | 2.80B | 2.87B | 2.92B | 3.32B | 3.05B | 3.20B | 2.99B | 2.19B | 1.96B | 1.78B | 1.04B |
| General & Administrative | 1.29B | 1.08B | 933.00M | 966.00M | 899.00M | 762.00M | 833.00M | 805.00M | 1.16B | 1.54B | 2.55B | 1.64B | 2.11B | 1.91B | 1.86B | 1.65B | 1.51B | 1.42B | 1.30B | -815.80M |
| Selling & Marketing | 7.48B | 6.61B | 5.89B | 5.95B | 5.51B | 5.28B | 5.65B | 5.49B | 6.71B | 4.87B | 4.20B | 5.27B | 4.02B | 3.50B | 3.17B | 2.46B | 2.41B | 2.42B | 2.34B | 1.44B |
| SG&A | 8.78B | 7.69B | 6.82B | 6.91B | 6.41B | 6.04B | 6.48B | 6.29B | 7.87B | 6.41B | 6.75B | 6.92B | 6.13B | 5.41B | 5.04B | 4.11B | 3.92B | 3.84B | 3.64B | 628.00M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 59.00M | 514.00M | 44.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 595.50M | 368.90M | 309.80M | 328.20M | 4.58B |
| Operating Expenses | 12.23B | 11.44B | 10.64B | 11.52B | 10.04B | 9.36B | 9.19B | 9.26B | 16.02B | 9.21B | 9.62B | 9.83B | 9.45B | 8.45B | 8.23B | 7.70B | 6.48B | 6.11B | 5.75B | 6.25B |
| Cost & Expenses | 16.72B | 15.39B | 14.29B | 15.68B | 13.43B | 12.82B | 13.07B | 13.34B | 21.41B | 13.37B | 13.66B | 13.16B | 12.61B | 11.41B | 10.89B | 9.54B | 8.68B | 7.75B | 7.24B | 7.18B |
| Interest Income | 86.00M | 22.00M | 7.00M | 6.00M | 39.00M | 29.00M | 183.00M | 172.00M | 288.00M | 310.00M | 154.00M | 13.00M | 116.00M | 137.00M | 370.00M | 419.40M | 337.10M | 250.10M | 458.50M | 82.70M |
| Interest Expense | 97.00M | 103.00M | 153.00M | 181.00M | 24.00M | 29.00M | 314.00M | 307.00M | 478.00M | 465.00M | 281.00M | 85.00M | 212.00M | 205.00M | 178.00M | 1.02B | 724.10M | 564.00M | 795.10M | 23.00M |
| Depreciation & Amortization | 2.01B | 1.81B | 1.71B | 2.79B | 1.67B | 1.18B | 1.25B | 1.34B | 7.03B | 310.00M | 154.00M | 901.00M | 116.00M | 1.17B | 856.00M | -604.80M | -387.00M | -313.90M | -336.60M | 599.10M |
| EBITDA | 5.10B | 4.45B | 3.51B | 4.95B | 4.78B | 5.29B | 5.62B | 3.58B | 498.00M | 1.86B | 1.75B | 2.55B | 4.29B | 4.53B | 3.50B | 2.98B | 2.31B | 1.47B | 1.85B | 3.09B |
| EBITDA Ratio | 25.62% | 25.17% | 22.30% | 27.12% | 22.19% | 27.02% | 25.24% | 25.70% | 3.41% | 3.04% | 11.49% | 17.21% | 21.92% | 30.68% | 27.02% | 15.48% | 21.01% | 15.94% | 20.21% | 32.39% |
| Operating Income | 3.20B | 2.85B | 2.01B | 1.99B | 3.61B | 5.30B | 4.41B | 2.29B | -6.53B | 99.00M | 1.60B | 1.65B | 3.39B | 3.36B | 2.86B | 2.35B | 2.70B | 1.78B | 2.17B | 2.55B |
| Operating Income Ratio | 16.05% | 15.63% | 12.33% | 11.26% | 20.79% | 29.66% | 25.58% | 14.66% | -44.73% | 0.74% | 10.48% | 11.13% | 21.20% | 22.74% | 20.79% | 20.84% | 24.54% | 19.35% | 23.92% | 26.24% |
| Total Other Income/Expenses | -202.00M | -378.00M | -429.00M | -84.00M | -127.00M | -12.00M | -131.00M | -135.00M | -478.00M | -155.00M | -127.00M | -65.00M | -96.00M | -68.00M | -192.00M | -71.00M | -133.90M | -151.20M | 72.30M | -32.40M |
| Income Before Tax | 2.99B | 2.47B | 1.58B | 1.91B | 3.48B | 5.29B | 4.28B | 2.16B | -7.01B | -56.00M | 1.47B | 1.58B | 3.30B | 3.29B | 2.67B | 2.12B | 2.56B | 1.63B | 2.26B | 2.52B |
| Income Before Tax Ratio | 15.03% | 13.56% | 9.70% | 10.79% | 20.05% | 29.59% | 24.82% | 13.80% | -48.01% | -0.42% | 9.65% | 10.69% | 20.60% | 22.28% | 19.39% | 18.82% | 23.32% | 17.71% | 24.87% | 25.90% |
| Income Tax Expense | 703.00M | 558.00M | 263.00M | 325.00M | 814.00M | 1.38B | 1.65B | 946.00M | -1.31B | 97.00M | 617.00M | 475.00M | 1.02B | 823.00M | 659.00M | -613.30M | -792.00M | -525.90M | -667.40M | 832.30M |
| Net Income | 2.29B | 1.92B | 1.32B | 1.58B | 2.67B | 3.91B | 2.62B | 1.21B | -5.69B | -153.00M | 855.00M | 1.11B | 2.28B | 2.47B | 2.01B | 2.74B | 3.35B | 2.16B | 2.92B | 1.71B |
| Net Income Ratio | 11.50% | 10.50% | 8.09% | 8.95% | 15.36% | 21.86% | 15.23% | 7.75% | -39.02% | -1.14% | 5.60% | 7.48% | 14.26% | 16.70% | 14.60% | 24.25% | 30.53% | 23.41% | 32.23% | 17.56% |
| EPS | 2.31 | 1.93 | 1.66 | 1.99 | 2.91 | 19.67 | 13.28 | 6.14 | -28.98 | -0.78 | 4.36 | 5.94 | 11.63 | 12.57 | 10.24 | 13.90 | 16.36 | 10.23 | 13.02 | 7.44 |
| EPS Diluted | 2.31 | 1.93 | 1.66 | 1.99 | 2.91 | 19.66 | 13.26 | 6.13 | -28.95 | -0.78 | 4.36 | 5.94 | 11.63 | 12.57 | 10.24 | 13.90 | 16.36 | 10.23 | 12.99 | 7.43 |
| Weighted Avg Shares Out | 992.24M | 992.87M | 794.64M | 794.92M | 794.77M | 198.68M | 197.51M | 197.19M | 196.47M | 196.25M | 196.14M | 196.13M | 196.10M | 196.12M | 196.12M | 196.84M | 204.99M | 211.10M | 224.56M | 229.61M |
| Weighted Avg Shares Out (Dil) | 992.24M | 992.87M | 794.64M | 794.93M | 794.86M | 198.74M | 197.79M | 197.41M | 196.71M | 196.39M | 196.18M | 196.14M | 196.10M | 196.12M | 196.12M | 196.84M | 204.99M | 211.10M | 225.07M | 229.83M |
Source: https://incomestatements.info
Category: Stock Reports